Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook

Edwards Lifesciences Corp

2023-FY EPS reported $2.30 revenue$6,004,800,000

Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).
Q4 GAAP EPS $0.61, adjusted EPS $0.64; full-year 2023 EPS $2.30 (GAAP), $2.51 adjusted.
TMTT sales $56M in Q4, $198M full year (+65% constant currency); EVOQUE received FDA approval for tricuspid regurgitation.
2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80; Q1 sales $1.53-1.61B.
Repurchased $444M in Q4, $867M in 2023; $1B remaining authorization; cash $1.6B, debt $600M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edwards Lifesciences Corp reported the year ended December 31, 2023 results: revenue $6.0 billion, EPS $2.30.

Period: the year ended December 31, 2023
Revenue: $6.0 billion
EPS: $2.30
Result: reported results

Exact text from the filing

Sales for the year ended December 31, 2023, were $6.0 billion, a year-over-year increase of 12 percent on both a reported and constant currency basis. Diluted earnings per share for 2023 were $2.30, while adjusted earnings per share were $2.51 .

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edwards Lifesciences Corp reported the quarter ended December 31, 2023 results: revenue $1.53 billion, EPS $0.61.

Period: the quarter ended December 31, 2023
Revenue: $1.53 billion
EPS: $0.61
Result: reported results

Exact text from the filing

Feb. 6, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook • Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent • Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent • Q4 EPS of $0.61; adjusted 1 EPS of $0.64 • 2023 sales of

View on SEC.gov

Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.